Primary source: View
The European Public Assessment Report (EPAR) for Benlysta has been revised to include important information regarding its indications and safety communications.
The updates to Benlysta’s indications will necessitate changes to labeling and safety communications, impacting how healthcare providers prescribe and monitor the drug.
Stakeholders must review and update the labeling of Benlysta in accordance with the new indications highlighted in the EPAR.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Stakeholders must review and update the labeling of Benlysta in accordance with the new indications highlighted in the EPAR.
Benlysta, authorized for use in the EU, serves as additional treatment for individuals aged 5 and older with systemic lupus erythematosus (SLE) and lupus nephritis. This update outlines the effective date of its authorization and its intended uses, emphasizing essential safety information.
What changed: The European Public Assessment Report (EPAR) for Benlysta has been revised to include important information regarding its indications and safety communications.
Why it matters: The updates to Benlysta’s indications will necessitate changes to labeling and safety communications, impacting how healthcare providers prescribe and monitor the drug.
Practical implication: Stakeholders must review and update the labeling of Benlysta in accordance with the new indications highlighted in the EPAR.
Published from the regulator source ingestion pipeline after PV impact triage.
Update labeling and handle regulatory documentation to reflect the new approved indication for sevabertinib, including dosage guidance of 20 mg orally twice daily.
Review and adjust labeling and compliance processes for affected combination products as per the new regulations.
Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.
Stakeholders should prepare for discussions regarding veterinary medicinal product reviews, specifically focusing on maximum residue limits and ensure all interests are declared by participants.
